Skip to Content
Merck
CN
  • Somatostatinoma syndrome. Biochemical, morphologic and clinical features.

Somatostatinoma syndrome. Biochemical, morphologic and clinical features.

The New England journal of medicine (1979-08-09)
G J Krejs, L Orci, J M Conlon, M Ravazzola, G R Davis, P Raskin, S M Collins, D M McCarthy, D Baetens, A Rubenstein, T A Aldor, R H Unger
PMID377080
ABSTRACT

Diabetes mellitus, steatorrhea, cholelithiasis and a tumor distorting the duodenum prompted a work-up for somatostatinoma in a 52-year-old man. The responses of pancreatic B-cells but not of A-cells to nutrient stimuli were inhibited, and growth-hormone release was suppressed, suggesting somatostatin resistance in some target tissues. Plasma somatostatin-like immunoreactivity ranged from 9000 to 13,000 pg per milliliter (normal: 88+/-8, mean +/- S.E.M.) and was distributed in four molecular forms, including free somatostatin. The primary tumor contained 5 microgram of somatostatin-like immunoreactivity per milligram of wet tissue, distributed in three of the molecular forms noted in plasma. Plasma calcitonin was also elevated (4650 pg per milliliter; normal: less than 120). Immunocytochemical studies showed that cells of the primary tumor contained somatostatin and calcitonin but no other peptide hormones. Only somatostatin was present in the metastases. Somatostatin was localized electron microscopically in all secretory granules, irrespective of size and shape, whereas calcitonin was present only within a single subpopulation of small granules in the same cells.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Somatostatin (EP130) Rabbit Monoclonal Primary Antibody